Anti-inflammatory Effect of Galectin-1 in a Murine Model of Atopic Dermatitis
Overview
Affiliations
Key Messages: Pharmacological treatment with rGal-1 reduces clinical signs of atopic dermatitis. Systemic treatment with rGal-1 inhibits eosinophil and mast cell influx in the skin of AD animals. rGal-1 reduced local eotaxin levels and systemic IL-17 levels. The inhibition of disease progression induced by rGal-1 was correlated with upregulation of phosphorylated ERK.
Neutrophils in Atopic Dermatitis.
Chiang C, Cheng W, Dela Cruz J, Raviraj T, Wu N, Korinek M Clin Rev Allergy Immunol. 2024; 67(1-3):21-39.
PMID: 39294505 PMC: 11638293. DOI: 10.1007/s12016-024-09004-3.
Nowowiejska J, Baran A, Hermanowicz J, Sieklucka B, Pawlak D, Flisiak I Biomolecules. 2023; 13(10).
PMID: 37892153 PMC: 10604582. DOI: 10.3390/biom13101472.
Paraquat Induces Lung Injury miR-199-Mediated SET in a Mouse Model.
Cai Q, Jin Y, Jia Z, Liu Z Front Pharmacol. 2022; 13:856441.
PMID: 35431948 PMC: 9011139. DOI: 10.3389/fphar.2022.856441.
Enhanced Susceptibility of Galectin-1 Deficient Mice to Experimental Colitis.
Fernandez-Perez R, Lopez-Santalla M, Sanchez-Dominguez R, Alberquilla O, Gutierrez-Canas I, Juarranz Y Front Immunol. 2021; 12:687443.
PMID: 34262567 PMC: 8273429. DOI: 10.3389/fimmu.2021.687443.
The Role of Galectin-9 as Mediator of Atopic Dermatitis: Effect on Keratinocytes.
Correa M, Areias L, Correia-Silva R, DAvila S, Leopoldino A, Greco K Cells. 2021; 10(4).
PMID: 33923930 PMC: 8073283. DOI: 10.3390/cells10040947.